Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 8/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | STAMBP | O95630 | 1/20 | 0.35 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31712859 | 0.83 | NNMT (0.48) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL31712856 | 0.81 | NNMT (0.40) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL16495711 | 0.65 | NNMT (0.56) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL23576533 | 0.65 | NNMT (0.44) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL28114582 | 0.63 | PSMD14 (0.47) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL2009043 | 0.62 | PARP1 (0.44) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL21061877 | 0.62 | NPC1 (0.41) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL2561709 | 0.62 | PSMD14 (0.46) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL30640966 | 0.62 | PARP1 (0.44) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 | |
| SCHEMBL17675163 | 0.62 | NNMT (0.58) | NNMTSMN1; SMN2PSMD14STAMBPCOPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | claimed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | NNMT 703/4885SMN1; SMN2 2918/4885PSMD14 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.